Clinical Trials Using Durvalumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Durvalumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-50 of 130

  • Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

    This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy.
    Location: 8 locations

  • Canakinumab with Chemoradiation and Durvalumab for the Treatment of Stage IIIA-C Non-Small Cell Lung Cancer, CHORUS Study

    This phase I / II study assesses the effectiveness and side effects of canakinumab with chemoradiation and durvalumab in treating patients with stage IIIA-C non-small cell lung cancer. Canakinumab is a monoclonal antibody that blocks a protein in the body called IL-1beta that can cause tumors to grow. Some studies have found that IL-1beta creates an environment that prevents the immune system from attacking tumors, and may play a role in causing tumors to spread beyond their original location to other parts of the body. The chemotherapy drugs that are part of the chemoradiation in this study work by targeting the processes that cancer cells use to grow and spread. Durvalumab is a PD-L1 inhibitor. It attaches to a protein, PD-L1, that acts as a shield and prevents cancer cells from being attacked by the immune system. When durvalumab attaches to PD-L1, it can break up the protective shield and help the immune system recognize and kill cancer cells. Giving canakinumab with chemoradiation therapy and durvalumab may be more effective in treating the cancer and stopping the tumor from growing compared to standard chemoradiation and durvalumab.
    Location: 7 locations

  • Treating Early-Stage Non-small Cell Lung Cancer with Durvalumab and Radiation Therapy

    This phase II trial studies the effects of stereotactic body radiation therapy and durvalumab in treating high-risk, stage I-IIIA non-small cell lung cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Durvalumab is a PD-L1 inhibitor. PD-L1 is a protein found on tumor cells and some immune cells that acts as a shield that prevents cancer cells from being attacked by the immune system. When durvalumab attaches to PD-L1, it can break up the protective shield and help the immune system recognize and kill the cancer cells. Stereotactic body radiation therapy and durvalumab may stop the cancer from getting worse (progressing).
    Location: 7 locations

  • Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors with Selected Mutations

    This phase Ib trial studies side effects and best dose of copanlisib and olaparib when given together with durvalumab, and how well they work in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combinations of copanlisib and olaparib or copanlisib, olaparib, and durvalumab may work better in treating patients with solid tumors compared to usual treatments such as surgery, radiation, or other chemotherapy drugs.
    Location: 8 locations

  • Olaparib and Durvalumab in Treating Patients with Non-metastatic Prostate Cancer

    This phase II trial studies how well combination of olaparib and durvalumab works in treating patients with prostate cancer that has not spread to other places in the body (non-metastatic). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving olaparib and durvalumab may work better in treating patients with prostate cancer compared to the usual treatment for this type of disease (antiandrogen therapy or radiation therapy or observation until PSA progression).
    Location: 7 locations

  • A Study of Neoadjuvant / Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

    This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.
    Location: 7 locations

  • Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

    This clinical study will assess the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with administered fixed doses of durvalumab in participants with relapsed / refractory solid tumor malignancies or lymphoma, as well as the objective response rate (ORR) of mRNA-2416 alone or in combination with durvalumab in ovarian cancer based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The applicable dose of mRNA-2416 will be injected directly into the participant's tumor (intratumoral) and the applicable dose of durvalumab will be administered intravenously.
    Location: 8 locations

  • Radiation Therapy in Combination with Durvalumab for the Treatment of Locally Advanced Pancreatic Cancer

    This phase I / II trial studies the effect of durvalumab and stereotactic ablative body radiotherapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). Durvalumab is a PD-L1 inhibitor. It attaches to a protein, programmed death-ligand 1 (PD-L1), which is found on tumor cells and some immune cells. PD-L1 acts as a shield that prevents cancer cells from being attacked by the immune system. When durvalumab attaches to PD-L1, it can break up the protective shield and help the immune system recognize and kill cancer cells. Stereotactic ablative body radiotherapy is a standard radiation treatment (radiotherapy) that uses high-energy x-rays to target tumors while limiting the radiation to the surrounding organs. Stereotactic ablative body radiotherapy may boost the immune system’s ability to fight cancer. Giving durvalumab and stereotactic ablative body radiotherapy may help destroy the tumor cells in patients with pancreatic cancer.
    Location: 7 locations

  • Durvalumab and Tremelimumab in Treating Patients with Relapsed or Refractory Germ Cell Tumors

    This phase II trial studies how well durvalumab and tremelimumab work in treating patients with germ cell tumors that have returned after a period of improvement (relapsed) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 7 locations

  • Durvalumab, an Anti-PDLI Antibody, Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation before Surgery for Esophageal Cancer

    This phase Ib / II trial studies the side effects of durvalumab when given together with chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal junction cancer. Both durvalumab and tremelimumab are antibodies (proteins) which bind to cells involved in the immune system. Antibodies are normally made by the body to destroy germs, like bacteria and viruses. The antibodies in this study are designed to boost the body’s immune system, by allowing immune cells to be more active and fight the cancer. Durvalumab works by interacting with an immune molecule called PD-L1, located on the tumor cells and white blood cells. Tremelimumab works by interacting with an immune molecule called CTLA-4, located on white blood cells. Both durvalumab and tremelimumab may help strengthen the immune system. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin, carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab together with chemotherapy and radiation therapy before surgery may work better at treating patients with esophageal or gastroesophageal junction cancer.
    Location: 7 locations

  • Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012 / KEYLYNK-012)

    The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. The primary hypotheses are: 1. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall survival (OS) 2. pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is superior to concurrent chemoradiation therapy followed by durvalumab with respect to PFS and OS
    Location: 6 locations

  • Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

    This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).
    Location: 7 locations

  • A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed / Refractory B-cell Malignancies (PLATFORM)

    This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1 / 2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents. This protocol is intended to evaluate various drug combinations with JCAR017, as separate arms, over the life of the protocol, using the same objectives. Each combination will be evaluated separately (ie, the intention is not to compare between combinations) for the purposes of the objectives, trial design, and statistical analysis. The following combinations will be tested: Arm A: JCAR017 in combination with durvalumab Arm B: JCAR017 in combination with CC-122 (avadomide) Arm C: JCAR017 in combination with CC-220 (iberdomide) Arm D: JCAR017 in combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and / or nivolumab Arm F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment once combination agents have been selected. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.
    Location: 7 locations

  • Ascending Doses of Ceralasertib in Combination With Chemotherapy and / or Novel Anti Cancer Agents

    This is a modular, phase I / phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and / or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is ceralasertib with carboplatin. The second combination to be investigated is ceralasertib with Olaparib. The third combination to be investigated is ceralasertib with durvalumab
    Location: 7 locations

  • Durvalumab or Placebo in Combination With Gemcitabine / Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

    Durvalumab or Placebo in Combination With Gemcitabine / Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
    Location: 5 locations

  • Durvalumab and Tremelimumab for Pediatric Malignancies

    The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.
    Location: 5 locations

  • A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

    Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced / metastatic solid tumors.
    Location: 4 locations

  • ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder

    A multi-arm multi-stage (MAMS) phase 1 / 2 study. Phase 1 will be conducted in BCG-unresponsive NMIBC patients to establish the safety of durvalumab monotherapy (cohort 1) and durvalumab in combination with BCG (cohort 2a) and external beam radiation therapy (EBRT) (cohort 2b). Provided safety is demonstrated and recommended phase 2 doses (RP2D) are established in phase 1, the study will proceed to phase 2 testing. Phase 2 will be conducted in the BCG-relapsing or persistent NMIBC population. In phase 2, BCG-relapsing or persistent NMIBC subjects will be randomized between treatment arms examining intravesical BCG in combination with novel immunotherapy agents (durvalumab), novel immunotherapy in combination with radiation (durvalumab + EBRT), or retreatment with intravesical BCG. In addition to providing additional safety data on the combination regimens studied, phase 2 will provide preliminary efficacy profiles for BCG-relapsing or persistent NMIBC subjects with and without CIS treated with each regimen. For regimens demonstrating a tolerable safety profile and encouraging clinical activity in this phase 1 / 2 design, a randomized phase 3 trial of experimental arm therapy versus re-treatment with intravesical BCG therapy would be considered.
    Location: 7 locations

  • A Phase 1 / 2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

    This is a two-part Phase 1 / 2 dose escalation and dose expansion study of the GMCSF-encoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.
    Location: 4 locations

  • A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

    This is an open-label, multicenter Phase 1 / 2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
    Location: 4 locations

  • Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

    This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC / GEJC) (MATTERHORN).
    Location: 4 locations

  • A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
    Location: 3 locations

  • Platinum-Based Chemotherapy and Durvalumab for the Treatment of Patients with Stage IIIB or IV Non-small Cell Lung Cancer

    This phase II trial studies how well platinum-based chemotherapy works when given together with durvalumab in treating patients with stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to find out if the combination of chemotherapy in combination with the immune therapy drug durvalumab would be efficacious and have an acceptable toxicity profile in patients with advanced non-small cell lung cancer.
    Location: 4 locations

  • Durvalumab, Tremelimumab, and Radiation Therapy in Treating Patients with Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma or Biliary Tract Cancer

    This phase II trial studies how well durvalumab, tremelimumab, and radiation therapy work in treating patients with hepatocellular carcinoma or biliary tract cancer that cannot be removed via surgery (unresectable) or that has spread to other parts of the body (metastatic). Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving durvalumab, tremelimumab, and radiation therapy may work better than radiation therapy alone in treating patients with hepatocellular carcinoma or biliary tract cancer.
    Location: 3 locations

  • Durvalumab, Tremelimumab, and Radiation Therapy in Treating Participants with High Risk Soft-Tissue Sarcoma

    This phase I / II trial studies the side effects of durvalumab, tremelimumab, and radiation therapy and to see how well they work in treating participants with high risk soft-tissue sarcoma. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab, tremelimumab, and radiation therapy may work better at treating high risk soft-tissue sarcoma.
    Location: 3 locations